REGENXBIO (NASDAQ:RGNX) Price Target Lowered to $50.00 at Chardan Capital

REGENXBIO (NASDAQ:RGNX) had its target price lowered by Chardan Capital from $52.00 to $50.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities analysts also recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Royal Bank Of Canada raised their target price on shares of REGENXBIO from $17.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday, November 7th. Leerink Partners boosted their target price on shares of REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Stifel Nicolaus raised their price target on REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $27.80.

REGENXBIO Price Performance

Shares of NASDAQ:RGNX opened at $8.85 on Tuesday. The stock has a market capitalization of $447.99 million, a P/E ratio of -2.55 and a beta of 1.05. The business has a 50-day moving average of $13.36 and a two-hundred day moving average of $11.43. REGENXBIO has a fifty-two week low of $5.03 and a fifty-two week high of $16.19.

Hedge Funds Weigh In On REGENXBIO

Several large investors have recently added to or reduced their stakes in RGNX. JPMorgan Chase & Co. grew its holdings in shares of REGENXBIO by 4.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after purchasing an additional 185,223 shares in the last quarter. Vanguard Group Inc. lifted its position in REGENXBIO by 1.1% in the fourth quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock worth $48,588,000 after purchasing an additional 36,042 shares during the period. Assenagon Asset Management S.A. lifted its position in REGENXBIO by 64.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock worth $16,709,000 after purchasing an additional 454,977 shares during the period. Geode Capital Management LLC boosted its stake in REGENXBIO by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 1,145,206 shares of the biotechnology company’s stock worth $16,495,000 after buying an additional 19,658 shares in the last quarter. Finally, Integral Health Asset Management LLC increased its holdings in REGENXBIO by 57.1% in the 3rd quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $10,615,000 after buying an additional 400,000 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.